---

         T R O U B L E D   C O M P A N Y   R E P O R T E R

              Saturday, January 6, 2024, Vol. 28, No. 5

                            Headlines

PROTERRA INC: Proterra OpCo. Widens Net Loss to $49.5M in November
SVB FINANCIAL: Narrows Net Loss in November to $7.6 Million
TIMBER PHARMACEUTICALS: Posts $1.42 Million Net Loss in November

                            *********

PROTERRA INC: Proterra OpCo. Widens Net Loss to $49.5M in November
------------------------------------------------------------------
Proterra Operating Company, a debtor affiliate of Proterra Inc.,
filed with the U.S. Securities and Exchange Commission its monthly
operating report for November 2023.

The Debtor's statement of operations reflected a net loss of $49.5
million for the current reporting period, an increase from the
previous net loss of $38.3 million in October.

As of November 30, 2023, the Debtor listed $631.1 million in total
assets, $441.6 million in total liabilities, and $189.5 million in
total shareholders' equity.

The Debtor started the month with $138.9 million cash. It listed
total cash receipts of $12.7 million and total disbursements of
$39.6 million. At month end, the Debtor had $112 million cash.

A copy of the monthly operating report is available at the SEC at:

                   http://tinyurl.com/2f3ma9td

                     About Proterra Inc.

Proterra Inc.'s business involves designing, manufacturing, and
selling electric transit buses and components, batteries, and
electric drive trains, and providing and selling related products
and services.

Proterra Inc. and Proterra Operating Company, Inc., sought relief
under Chapter 11 of the U.S. Bankruptcy Code (Bankr. D. Del. Lead
Case No. 23-11120) on August 7, 2023. In the petition filed by
Gareth T. Joyce, chief executive officer, the Debtor reported total
assets as of June 30, 2023 amounting to $818,773,679 and total debt
as of June 30, 2023 of $609,498,207.

The Honorable Bankruptcy Judge Brendan Linehan Shannon handles the
cases.

The Debtors tapped Young Conaway Stargatt & Taylor, LLP, and Paul,
Weiss, Rifkind, Wharton & Garrison LLP, as counsel; FTI Consulting,
Inc., as financial advisor; Moelis & Company, LLC, as investment
banker; and Slaughter and May as special corporate counsel.
Kurtzman Carson Consultants LLC is the claims agent.


SVB FINANCIAL: Narrows Net Loss in November to $7.6 Million
-----------------------------------------------------------
SVB Financial Group filed with the U.S. Securities and Exchange
Commission its monthly operating report for November 2023.

The Debtor's statement of operations reflected a net loss of $7.6
million for November, a big dip from October's $41.6 million net
loss.

As of November 30, 2023, the Debtor listed $3.64 billion in total
assets, $3.57 billion in total liabilities, and $70.4 million in
total shareholders' equity.

The Debtor started the month with $241.9 million cash. It listed
total cash receipts of $81 million and total disbursements of $41.4
million. At month end, the Debtor had $281.5 million cash.

A copy of the monthly operating report is available at the SEC at:

                   http://tinyurl.com/yc67u93

                  About SVB Financial Group

SVB Financial Group is a financial services company focusing on the
innovation economy, offering financial products and services to
clients across the United States and in key international markets.

Prior to March 10, 2023, SVB Financial Group owned and operated
Silicon Valley Bank, a state-chartered bank.  During the week of
March 6, 2023, Silicon Valley Bank, Santa Clara, CA, experienced a
severe "run-on-the-bank."  On the morning of March 10, the
California Department of Financial Protection and Innovation seized
SVB and placed it under the receivership of the Federal Deposit
Insurance Corporation.  SVB was the nation's 16th largest bank and
the biggest to fail since the 2008 financial meltdown.

On March 17, 2023, SVB Financial Group sought Chapter 11 bankruptcy
protection (Bankr. S.D.N.Y. Case No. 23-10367).  The Debtor had
assets of $19,679,000,000 and liabilities of $3,675,000,000 as of
Dec. 31, 2022.

The Hon. Martin Glenn is the bankruptcy judge.

The Debtor tapped Sullivan & Cromwell, LLP as bankruptcy counsel;
Centerview Partners, LLC as investment banker; and Alvarez & Marsal
North America, LLC as restructuring advisor.  William Kosturos, a
partner at Alvarez & Marsal, serves as the Debtor's chief
restructuring officer.  Kroll Restructuring Administration, LLC, is
the claims and noticing agent and administrative advisor.

The U.S. Trustee for Region 2 appointed an official committee to
represent unsecured creditors in the Debtor's Chapter 11 case.  The
committee tapped Akin Gump Strauss Hauer & Feld, LLP as bankruptcy
counsel; Cole Schotz P.C. as conflict counsel; Lazard Freres & Co.,
LLC as investment banker; and Berkeley Research Group, LLC as
financial advisor.


TIMBER PHARMACEUTICALS: Posts $1.42 Million Net Loss in November
----------------------------------------------------------------
Timber Pharmaceuticals, Inc. filed with the U.S. Securities and
Exchange Commission its monthly operating report for November.

The Debtor's statement of operations reflected a net loss of $1.42
million for the current reporting period.

As of November 30, 2023, the Debtor listed $4.9 million in total
assets, $16.25 million in total liabilities, and -$11.35 million in
total shareholders' equity.

The Debtor started the month with $862,460 cash. It listed total
receipts of $3 million and total disbursements of $847,338. At
month end, the Debtor had $3.02 million cash.

A copy of the monthly operating report is available at the SEC at:

                   http://tinyurl.com/28j3du64

                 About Timber Pharmaceuticals

Timber Pharmaceuticals, Inc. f/k/a BioPharmX Corporation --
http://www.timberpharma.com-- is a biopharmaceutical company
focused on the development and commercialization of treatments for
orphan dermatologic diseases.  The Company's investigational
therapies have proven mechanisms-of-action backed by decades of
clinical experience and well-established CMC (chemistry,
manufacturing and control) and safety profiles.  The Company is
initially focused on developing non-systemic treatments for rare
dermatologic diseases including congenital ichthyosis (CI), facial
angiofibromas (FAs) in tuberous sclerosis complex (TSC), and
localized scleroderma.

Timber Pharmaceuticals, Inc., and affiliates Timber Pharmaceuticals
LLC and BioPharmX Inc. sought Chapter 11 protection (Bankr. D. Del.
Lead Case No. 23-11878) on Nov. 17, 2023.  Timber Pharmaceuticals,
Inc., disclosed total assets of $3,326,213 against total debt of
$5,947,297.

The Debtors tapped Morris, Nichols, Arhst & Tunnell LLP as
bankruptcy counsel; Lowenstein Sandler LLP as special counsel; and
VRS Restructuring Services LLC to provide a chief restructuring
officer.

Counsel to the DIP Lender, LEO US Holding, Inc., are Covington &
Burling LLP and Cole Shotz P.C.


                            *********

Monday's edition of the TCR delivers a list of indicative prices
for bond issues that reportedly trade well below par.  Prices are
obtained by TCR editors from a variety of outside sources during
the prior week we think are reliable.  Those sources may not,
however, be complete or accurate.  The Monday Bond Pricing table
is compiled on the Friday prior to publication.  Prices reported
are not intended to reflect actual trades.  Prices for actual
trades are probably different.  Our objective is to share
information, not make markets in publicly traded securities.
Nothing in the TCR constitutes an offer or solicitation to buy or
sell any security of any kind.  It is likely that some entity
affiliated with a TCR editor holds some position in the issuers
public debt and equity securities about which we report.

Each Tuesday edition of the TCR contains a list of companies with
insolvent balance sheets whose shares trade higher than $3 per
share in public markets.  At first glance, this list may look like
the definitive compilation of stocks that are ideal to sell short.
Don't be fooled.  Assets, for example, reported at historical cost
net of depreciation may understate the true value of a firm's
assets.  A company may establish reserves on its balance sheet for
liabilities that may never materialize.  The prices at which
equity securities trade in public market are determined by more
than a balance sheet solvency test.

On Thursdays, the TCR delivers a list of recently filed
Chapter 11 cases involving less than $1,000,000 in assets and
liabilities delivered to nation's bankruptcy courts.  The list
includes links to freely downloadable images of these small-dollar
petitions in Acrobat PDF format.

Each Friday's edition of the TCR includes a review about a book of
interest to troubled company professionals.  All titles are
available at your local bookstore or through Amazon.com.  Go to
http://www.bankrupt.com/books/to order any title today.

Monthly Operating Reports are summarized in every Saturday edition
of the TCR.

The Sunday TCR delivers securitization rating news from the week
then-ending.

TCR subscribers have free access to our on-line news archive.
Point your Web browser to http://TCRresources.bankrupt.com/and use
the e-mail address to which your TCR is delivered to login.

                            *********

S U B S C R I P T I O N   I N F O R M A T I O N

Troubled Company Reporter is a daily newsletter co-published
by Bankruptcy Creditors Service, Inc., Fairless Hills,
Pennsylvania, USA, and Beard Group, Inc., Philadelphia, Pa., USA.
Randy Antoni, Jhonas Dampog, Marites Claro, Joy Agravante,
Rousel Elaine Tumanda, Joel Anthony G. Lopez, Psyche A. Castillon,
Ivy B. Magdadaro, Carlo Fernandez, Christopher G. Patalinghug, and
Peter A. Chapman, Editors.

Copyright 2024.  All rights reserved.  ISSN: 1520-9474.

This material is copyrighted and any commercial use, resale or
publication in any form (including e-mail forwarding, electronic
re-mailing and photocopying) is strictly prohibited without prior
written permission of the publishers.  Information contained
herein is obtained from sources believed to be reliable, but is
not guaranteed.

The TCR subscription rate is $975 for 6 months delivered via
e-mail.  Additional e-mail subscriptions for members of the same
firm for the term of the initial subscription or balance thereof
are $25 each.  For subscription information, contact Peter A.
Chapman at 215-945-7000.

                   *** End of Transmission ***